Human PIGF Recombinant Protein (HEK293 Expression) — Tag Free

⚡ Z-Active® Tagless Protein
In Stock · Ships Today
SKU: RP617

Price range: $198.00 through $5,600.00

Z-Active® HEK293 × Chaperone-Assisted Technology

Produced using our proprietary Z-Active® platform — HEK293 mammalian expression with chaperone-assisted folding for proper disulfide bonding, N-linked glycosylation, and 5–10× higher bioactivity vs Leading Suppliers.

✅ 5–10× Higher Bioactivity
✅ Proper Folding & Disulfide Bonds
✅ N-Linked Glycosylation
✅ Tag-Free, Native Conformation
Z-Active®
5–10×
Leading Suppliers
~1×
Size
SKU: RP617-10UG $198.00
Quality guaranteed
Ships within 24 hours

Overview

Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines (1, 2). Alternative splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively (1, 2). Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus (1). Human PlGF-1 shares 56%, 55%, 74% and 95% aa identity with the comparable isoform of mouse, rat, canine, and equine PlGF, respectively. PlGF is mainly found as variably glycosylated, secreted, 55-60 kDa disulfide linked homodimers (3). Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes, and some endothelial cells (1, 4-6). Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia (7). However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia (8).

Specifications

  • Species: human
  • Expression System: HEK293
  • Sequence: Ala21-Arg149
  • Tag: Tag Free
  • Molecular Weight: 14.5 KDa
  • Purity: > 95% by Tris-Bis PAGE;> 95% by SEC-HPLC
  • Endotoxin: < 1 EU/μg of the protein by LAL method.
  • UniProt/Swiss-Prot: Q07326
  • Available Sizes: 10 µg, 50 µg, 1 mg

Bioactivity

Measured by its binding ability in a functional ELISA. When Recombinant Human VEGF R1/Flt‑1 Fc Chimera (Catalog # 3516-FL) is immobilized at 0.5 μg/mL, 100 μL/well, the concentration of Recombinant Human PlGF that produces 50% of the optimal binding response is approximately 0.75-4.5 ng/mL.

Formulation & Reconstitution

Formulation: 0.22 μm filtered solution of PBS, pH 7.4.

Reconstitution: 0.2 mg/mL in sterile PBS, pH7.4

Storage & Stability

Aliquot and store at -80°C. Avoid repeated freeze/thaw cycles.

Quality Assurance

Each lot is tested for purity (SDS-PAGE, SEC-HPLC), endotoxin levels (LAL method), and bioactivity. A Certificate of Analysis (COA) is provided with every order.

Human PIGF (Human) expressed in HEK293. Tag Free. Purity: > 95% by Tris-Bis PAGE;> 95% by SEC-HPLC. Bioactivity: Measured by its binding ability in a functional ELISA. When Recombinant Human VE...

Safety Data Sheets & Documentation

Safety Data Sheet (SDS) PDF — RP617

Protocols & Support

Reconstitution Protocol

1. Briefly centrifuge the vial to collect lyophilized powder at the bottom.

2. Reconstitute in sterile deionized water or PBS to a concentration of 0.2–1.0 mg/mL.

3. Gently pipette up and down to dissolve. Do not vortex.

4. Aliquot and store at -20°C to -80°C. Avoid repeated freeze-thaw cycles.

Download Data Sheet

Complete product data sheet including batch-specific QC data, sequence information, and storage guidelines.

Download PDF Data Sheet